Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial (Q34551403)

3 August 2017

0 references

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial (English)

1 reference

3 August 2017

1 reference

6

Jean-Yves Blay

0 references

Rossella Bertulli

Rossella Bertulli

11

0 references

Paolo Giovanni Casali

Paolo G Casali

2

0 references

Rolf D Issels

Rolf Issels

7

1 reference

ORCID Public Data File 2021

Jaap Verweij

1

Jaap Verweij

1 reference

3 August 2017

Pancras C.W. Hogendoorn

9

Pancras C W Hogendoorn

1 reference

3 August 2017

3

John Zalcberg

1 reference

3 August 2017

12

Ian Judson

1 reference

3 August 2017

Axel LeCesne

4

1 reference

3 August 2017

Peter Reichardt

5

1 reference

3 August 2017

Allan van Oosterom

8

1 reference

3 August 2017

Martine Van Glabbeke

10

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

3 August 2017

1 reference

3 August 2017

364

1 reference

3 August 2017

9440

1 reference

3 August 2017

1127-1134

1 reference

Gastrointestinal stromal tumors--a review.

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

The histopathological differential diagnosis of gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

Management of malignant gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

A stagewise rejective multiple test procedure based on a modified Bonferroni test

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917098-0

7 January 2021

10.1016/S0140-6736(04)17098-0

Identifiers

DOI

1 reference

3 August 2017

1 reference